Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20914035 | 0.89 | MAT2A (0.34) | HPGDKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL20914059 | 0.88 | MAT2A (0.33) | HPGDKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL20836952 | 0.87 | MAT2A (0.33) | HPGDKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL20914077 | 0.86 | TNKS (0.37) | HPGDKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL20914099 | 0.86 | POLB (0.35) | KDM4EALDH1A1KMT2AMEN1MAT2A | |
| SCHEMBL20837047 | 0.82 | MAT2A (0.33) | HPGDKMT2AMEN1MAT2AHTT | |
| SCHEMBL20914308 | 0.80 | MAT2A (0.34) | KDM4EKMT2AMEN1MAT2ATSHR | |
| SCHEMBL20913982 | 0.80 | MAT2A (0.34) | KDM4EHSD17B10KMT2AMEN1MAT2A | |
| SCHEMBL20914019 | 0.80 | PLAT (0.32) | HPGDKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL20913968 | 0.80 | KDM4E (0.34) | HPGDKDM4EALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| CN-111212839-A | Pyrazolopyrimidinone compounds and uses thereof | 艾杜罗生物科技公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | HPGD 280/4885KDM4E 1922/4885ALDH1A1 1246/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | HPGD 280/4885KDM4E 1922/4885ALDH1A1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.